Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

UISS (UCLA Integrated Staging)

The UCLA Integrated Staging System (UISS) stratifies patients with localized (non-metastatic) renal cell carcinoma into three risk groups based on TNM Stage, Fuhrman Grade, and ECOG Performance Status.

Evidence-based context for fast calculator use

Purpose:
UISS stratifies localized renal cell carcinoma into risk groups using TNM stage, Fuhrman grade, and ECOG to predict post-nephrectomy survival.
Population:
patients undergoing localized or metastatic renal cell carcinoma prognostic assessment
Factors:
T-Stage, Fuhrman Grade, ECOG Performance Status, Nodal or Distant Metastasis?
Reference:
Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol. 2001;19(6):1649-1657.
HomeUISS (UCLA Integrated Staging)
Pin your most used calculators here by clicking the star in the dropdown.

UISS (UCLA Integrated Staging)

Clinical Context & Background

The UCLA Integrated Staging System (UISS) stratifies patients with localized (non-metastatic) renal cell carcinoma into three risk groups based on TNM Stage, Fuhrman Grade, and ECOG Performance Status. It predicts overall survival after nephrectomy.
Primary Source EvidenceZisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol. 2001;19(6):1649-1657.
Formula Logic
Risk group based on T-stage, Grade, and ECOG.

Reference Data

Risk GroupCriteria5-Year Survival
Low RiskT1-T2 N0 M0, Grade 1-2, ECOG 091%
Intermediate RiskAll other combinations80%
High RiskT3 N0 M0 or Grade 3-4 or ECOG ≥ 155%

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use UISS (UCLA Integrated Staging) when uISS stratifies localized renal cell carcinoma into risk groups using TNM stage, Fuhrman grade, and ECOG to predict post-nephrectomy survival.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning Low Risk through High Risk.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Confirm histology, localized versus metastatic setting, nephrectomy status, treatment line, and imaging before selecting surveillance or systemic-therapy pathways.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Post-nephrectomy and metastatic RCC models are not interchangeable.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients undergoing localized or metastatic renal cell carcinoma prognostic assessment

How to apply this result

For a representative case, verify T-Stage, Fuhrman Grade, ECOG Performance Status, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Kidney / Renal hubContinue to related calculators and clinical workflow resources.

Share This Calculator

Share:

Related Tools

IMDC (Heng) Risk Criteria Calculator — Metastatic Renal Cell CarcinomaMSKCC (Motzer) ScoreLeibovich Score (RCC)

Frequently Asked Questions

When should UISS (UCLA Integrated Staging) be used?

Use it for patients undergoing localized or metastatic renal cell carcinoma prognostic assessment when all required inputs and the intended clinical setting are confirmed.

Can UISS (UCLA Integrated Staging) determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.